Partnering with Patients: The Cornerstone of Cancer Care and Research

1 May 2023
16 May 2023

Read the latest in cancer care and research

At Wiley, we make oncology research more accessible improving patient care around the world. We help researchers advance the field by making life-changing research available to scientists, policy-makers, patients and those teaching the next generation of clinicians. Discover some of the latest advancements in the field collected into one themed issue inspired by the theme of this year's American Society of Clinical Oncology's Annual Meeting: Partnering with Patients: The Cornerstone of Cancer Care and Research.


Partnering with Patients: The Cornerstone of Cancer Care and Research

Hematologic Malignancies

Open Access

Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

Matching-adjusted indirect comparison results for Isa-Kd vs. Dara-Rd: Kaplan-Meier curves of progression-free survival before matching and after inclusion criteria selection (A) and after matching (B); Kaplan-Meier curves of overall survival before matching and after inclusion criteria selection (C) and after matching (D). CI, confidence interval; Dara-Rd, daratumumab + lenalidomide + dexamethasone; HR, hazard ratio; Isa-Kd, isatuximab + carfilzomib + dexamethasone. *Statistically significant at 0.05 level.

Open Access

Examining the utility of lower dose radiotherapy for localised primary ocular adnexal MALT lymphoma

Examining the utility of lower dose radiotherapy for localised primary ocular adnexal MALT lymphoma

We aimed to examine our institution’s experience with the use of orbital RT for treating early-stage primary ocular adnexal MALT lymphoma (POAML).The use of lower dose orbital RT such as 20 Gy in 10 fractions (or radio biologically equivalent) yields excellent local disease control in the management of ocular adnexal MALT lymphoma.

Open Access

Severe graft-versus-host disease post allogeneic hematopoietic stem cell transplantation due to loss of HLA heterozygosity in recipient lymphocytes after full graft rejection

Severe graft-versus-host disease post allogeneic hematopoietic stem cell transplantation due to loss of HLA heterozygosity in recipient lymphocytes after full graft rejection

This paper presents a unique case of a 13-year-old female patient diagnosed with concomitant germ cell tumors and acute lymphoblastic leukemia, who underwent allogeneic hematopoietic stem cell transplantation and subsequently developed severe graft-versus-host disease (GVHD)-like manifestations (hereon, we call GVH-like-disease, GVHLD) despite the absence of donor chimerism and recurrent hematological malignancy. The underlying etiology was found to be HLA loss of heterozygosity (HLA-LOH) in the patient's newly reconstituted hematopoietic lineage. This is the first report of fatal GVHLD caused by HLA-LOH in the recipient's own immune system without donor chimerism. The paper highlights the importance of understanding the role of HLA-LOH in GVHLD pathogenesis.

Open Access

Causal relationship between 14 site-specific cancers and venous thromboembolism

Causal relationship between 14 site-specific cancers and venous thromboembolism

Using Mendelian randomization study, we elucidated the causal effect between 14 site-specific cancers and venous thromboembolism. Non-Hodgkin's lymphoma increases risk of venous thromboembolism while melanoma decreases its risk. footnotes: VTE: venous thromboembolism; some icons were referenced from the Biorender (https://biorender.com/).

Lung Cancer

Open Access

Effectiveness and safety of Endostar combined with chemotherapy in treating advanced NSCLC patients with different ages

Effectiveness and safety of Endostar combined with chemotherapy in treating advanced NSCLC patients with different ages

Lung cancer ranks as the leading cause of cancer death in 2020 worldwide. Approximately 85% of newly diagnosed lung cancers are non-small cell lung cancer (NSCLC). However, the benefit of Endostar used in treating patients with advanced NSCLC of different ages is still unclear in real-world clinical settings. This study aimed to assess the effectiveness and safety of Endostar combined with chemotherapy in the treatment of patients with NSCLC in different age groups (≤60 years vs.>60 years) in a real-world study and indicated the potential of the combination of Endostar and chemotherapy in treating older patients with NSCLC in real clinical settings.

Free Access

Local thermal ablative therapies for extracranial oligometastatic disease of non-small-cell lung cancer

Local thermal ablative therapies for extracranial oligometastatic disease of non-small-cell lung cancer

Due to the concept of oligometastasis in lung cancer, thermal ablation combined with other therapies is gradually recognized.This article reviews the concept, classification, local treatment and prognosis of extracranial oligometastasis.

Open Access

Patterns of curative treatment for non-small cell lung cancer in New South Wales, Australia

Patterns of curative treatment for non-small cell lung cancer in New South Wales, Australia

The curative treatment for patients with potentially curable non-small cell lung cancer was low at 59% in New South Wales, Australia. Significant variation was noted in the use of curative treatment between local health districts (24%–70%).

Open Access

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation

Tepotinib have high retention in the tumor and sustained inhibition of MET and its downstream pathways. Tepotinib is a key drug for cancer patients with MET exon 14 skipping mutation. However, its bioavailability in the CSF in humans has not been elucidated. The blood brain barrier protects the CNS from toxicity, but also prevents therapeutic drugs from accessing the brain. We report a case of leptomeningeal metastasis successfully treated with tepotinib in a patient with poor PS and on the bioavailability of tepotinib in the CSF in humans.

Open Access

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Targeted therapy for EGFR-mutant lung cancers has been developed based on data regarding mainly common mutations. However, recent studies revealed that rare genotypes could be targetable if appropriate TKIs are selected.

Open Access

Marine toxin (+)-chaetocin-induced apoptosis of lung large cell carcinoma cell lines through cell cycle arrest via CDKN1A expression and replicative stress

Marine toxin (+)-chaetocin-induced apoptosis of lung large cell carcinoma cell lines through cell cycle arrest via CDKN1A expression and replicative stress

  1. Chaetocin demonstrated strong antineoplastic activities against non-small cell lung carcinoma cell lines.
  2. Cell cycle arrest via CDKN1A expression and the comprehensive replicative stress of Chaetocin would be key factors of Chaetocin working mechanisms.

Open Access

Lysophosphatidylcholine inhibits lung cancer cell proliferation by regulating fatty acid metabolism enzyme long-chain acyl-coenzyme A synthase 5

Lysophosphatidylcholine inhibits lung cancer cell proliferation by regulating fatty acid metabolism enzyme long-chain acyl-coenzyme A synthase 5

  1. LysoPC reprograms lipid metabolisms by increasing the accumulation of fatty acids and activating acyl-CoA-dominated metabolic mode under the control and regulation of ACSL5.
  2. LysoPC up-regulates the expression of ACSL5 and activates the ACSL5-oriented lipid metabolism by promoting the phosphorylation of PI3K/mTOR and Ras/ERK signal pathways.
  3. LysoPC inhibited lung cancer cell proliferation by promoting ACSL5, leading to the disorder of FA degradation.

Open Access

LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing

LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing

  • Abnormally high expression of BC correlates with poor survival of LUAD patients.
  • BC is involved in acquired resistance to EGFR-targeted therapies.
  • BC restores the epithelial–mesenchymal transition suppressed by IMPAD1.
  • BC promotes IMPAD1 alternative splicing via an interaction with hnRNPK and NCL.

Open Access

Clinical validation of a semi-automated segmentation algorithm for target volume definition on planning CT and CBCT in stereotactic body radiotherapy (SBRT) for peripheral lung lesions

Clinical validation of a semi-automated segmentation algorithm for target volume definition on planning CT and CBCT in stereotactic body radiotherapy (SBRT) for peripheral lung lesions

The Interobserver variability for target volume delineation in the SBRT of pulmonary lesions - could have major negative dosimetric consequences, which could threaten the tumour control probability. In this study, we introduce an easy-use semi-automated delineation tool for peripheral lung lesions in free breathing (FB) and four-dimensional (4D) planning CT and cone beam CT (CBCT). The Dice similarity coefficient (DSC) showed the reliability of the tool alone or better in a supervised application. The semi-automated delineation tool can accurately track the interfraction and intrafraction changes or deformations of tumours through the therapy in CBCT, opening the door for its use in adaptive planning.

Open Access

Volumetric modulated arc therapy (VMAT) comparison to 3D-conformal technique in lung stereotactic ablative radiotherapy (SABR)

Volumetric modulated arc therapy (VMAT) comparison to 3D-conformal technique in lung stereotactic ablative radiotherapy (SABR)

This paper evaluates the dosimetry of volumetric arc therapy in comparison to 3D-Conformal technique in delivery of lung stereotactic ablative radiotherapy. No significant dosimetric differences were found between the two techniqiues that could potentially lead to an increased risk of radiation pneumonitis.